WO2003087306A8 - Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer - Google Patents

Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Info

Publication number
WO2003087306A8
WO2003087306A8 PCT/US2003/010462 US0310462W WO03087306A8 WO 2003087306 A8 WO2003087306 A8 WO 2003087306A8 US 0310462 W US0310462 W US 0310462W WO 03087306 A8 WO03087306 A8 WO 03087306A8
Authority
WO
WIPO (PCT)
Prior art keywords
98p4b6
cancer
detection
useful
treatment
Prior art date
Application number
PCT/US2003/010462
Other languages
French (fr)
Other versions
WO2003087306A2 (en
Inventor
Pia M Challita-Eid
Mary Faris
Wangmao Ge
Aya Jakobovits
Arthur B Raitano
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US37038702P priority Critical
Priority to US60/370,387 priority
Priority to US10/165,044 priority patent/US20030149531A1/en
Priority to US10/165,044 priority
Priority to US60/435,480 priority
Priority to US43548002P priority
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of WO2003087306A2 publication Critical patent/WO2003087306A2/en
Priority claimed from IL164390A external-priority patent/IL164390A/en
Publication of WO2003087306A8 publication Critical patent/WO2003087306A8/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29255235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003087306(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
PCT/US2003/010462 2000-12-06 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer WO2003087306A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US37038702P true 2002-04-05 2002-04-05
US60/370,387 2002-04-05
US10/165,044 US20030149531A1 (en) 2000-12-06 2002-06-06 Serpentine transmembrane antigens expressed in human cancers and uses thereof
US10/165,044 2002-06-06
US43548002P true 2002-12-20 2002-12-20
US60/435,480 2002-12-20

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP03719599A EP1572916A4 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
MXPA04009728A MXPA04009728A (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer.
CA 2481503 CA2481503A1 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
BR0308953A BR0308953A (en) 2002-04-05 2003-04-04 compositions, protein, polynucleotide, method of generating an immune response detection method, pharmaceutical composition, antibody, or fragment thereof transgenic animal hybridoma supply method of a cytotoxic agent or diagnostic agent and method of inhibiting cell growth cancer
JP2003584250A JP2005534287A (en) 2002-04-05 2003-04-04 Name of the nucleic acid and corresponding protein with 98p4b6 useful in the treatment and detection of cancer
NZ53576203A NZ535762A (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98P4B6 (STEAP 2) useful in treatment and detection of cancer
AU2003223469A AU2003223469A1 (en) 2002-04-05 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
IL164390A IL164390A (en) 2002-04-05 2004-10-04 Compositions comprising a peptide with a substituted amino acid at a primary anchor site

Publications (2)

Publication Number Publication Date
WO2003087306A2 WO2003087306A2 (en) 2003-10-23
WO2003087306A8 true WO2003087306A8 (en) 2006-10-05

Family

ID=29255235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010462 WO2003087306A2 (en) 2000-12-06 2003-04-04 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Country Status (8)

Country Link
EP (1) EP1572916A4 (en)
JP (1) JP2005534287A (en)
AU (2) AU2003223469A1 (en)
BR (1) BR0308953A (en)
CA (1) CA2481503A1 (en)
MX (1) MXPA04009728A (en)
NZ (1) NZ535762A (en)
WO (1) WO2003087306A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
WO2006015165A2 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
SI1791565T1 (en) 2004-09-23 2016-08-31 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2010268690B2 (en) 2009-07-03 2011-11-10 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
US9315581B2 (en) 2009-12-23 2016-04-19 A Vipep Pty Limited Immuno-conjugates and methods for producing them
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
EP2699597B1 (en) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them b
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc antibody and conjugated drug, compound, method of treatment and pharmaceutical composition
MX2016007825A (en) 2013-12-16 2016-09-07 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, the method of preparation of a conjugate of formula, formula A1 conjugate, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition and use of a conjugate or a composition
AU2015358532A1 (en) 2014-12-03 2017-06-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3458101A1 (en) 2016-05-20 2019-03-27 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221A1 (en) 2016-05-27 2019-04-10 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
AU2017331361A1 (en) 2016-09-23 2019-04-11 Regeneron Pharmaceuticals, Inc. Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642909A3 (en) * 1999-12-06 2006-04-12 Agensys, Inc. Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
WO2001072962A2 (en) * 2000-03-24 2001-10-04 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
EP1572916A2 (en) 2005-09-14
EP1572916A4 (en) 2007-05-30
WO2003087306A2 (en) 2003-10-23
AU2009230789A1 (en) 2009-11-19
BR0308953A (en) 2006-03-14
CA2481503A1 (en) 2003-10-23
MXPA04009728A (en) 2005-06-08
JP2005534287A (en) 2005-11-17
NZ535762A (en) 2009-04-30
AU2003223469A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
AU781501C (en) Anti-alphavbeta3recombinant human antibodies, nucleic acids encoding same and methods of use
AU2003280444A1 (en) Combined activated sludge-biofilm sequencing batch reactor and process
EP1539275A4 (en) Blood aspiration system and methods of use
AU2003273171A1 (en) Immunomodulatory compounds and methods of use thereof
AU2003259195A1 (en) Methods and reagents for improved selection of biological materials
EP1576376A4 (en) Isolated communication sample processing system and methods of biological slide processing
AU2001297693A1 (en) Cpg-like nucleic acids and methods of use thereof
HK1057254A1 (en) Analyte concentration determination devices and methods of using the same
SI2053063T1 (en) Recognition molecules for treatment and detection of tumours
AU1935701A (en) Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
AU2002309528A1 (en) Blood glucose tracking apparatus and methods
AU2003212729A1 (en) Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
AU2002244862A1 (en) Diagnosis and treatment of cancer: I
AU2003275311A1 (en) Solid micro-perforators and methods of use
ZA200505306B (en) Complexes of protein crystals and ionic polymers
AU2003261231A8 (en) Modified small interfering rna molecules and methods of use
AU2002255511A1 (en) Charge tags and separation of nucleic acid molecules
AU2003247375A1 (en) Nucleic acid sequencing by signal stretching and data integration
AU2003256703A8 (en) Biosensor arrays and methods
AU2003240959A1 (en) Microarray detector and methods
AU2003215460A8 (en) Cancer associated protein kinases and their uses
AU2003227738A1 (en) Enzyme electrode array and biosensor array
AU2003267124A1 (en) Bh3 peptides and method of use thereof
AU1853600A (en) Method for the detection of gene transcripts in blood and uses thereof
AU2003303398A1 (en) Dowhole chemical sensor and method of using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2481503

Country of ref document: CA

Ref document number: 200407980

Country of ref document: ZA

Ref document number: 2004/07980

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009728

Country of ref document: MX

Ref document number: 2003584250

Country of ref document: JP

Ref document number: 535762

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003719599

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003223469

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038129876

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003719599

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0308953

Country of ref document: BR